Glucagon-like peptide-1 receptor agonists and aspiration risk: a narrative review
Various studies underscore the effectiveness of this medication, as well as its safety for a wide age range
Wegovy and Saxenda are meant for individuals with obesity, which is a Body Mass Index (BMI) of 30 or more, and for those who are overweight (BMI of 27 or more) with weight-related health issues like type 2 diabetes, high blood pressure, or high cholesterol
Recent studies highlight the risk of developing gastroparesis from GLP-1 medication use: Research unveiled at Digestive Week 2024 indicates a rise in gastroparesis occurrences in patients using GLP-1 drugs compared to those not taking these medications
Self-reported data represents people who chose to report, which may skew toward those with more notable results
CagriSema is a two-peptide fixed combination the amylin analogue cagrilintide co-administered with the GLP-1 receptor agonist semaglutide whereas tirzepatide is a single engineered molecule that activates two receptors (GIP and GLP-1) at once
.jpg)
